Fig. 3
From: Recent advances in therapeutic strategies for triple-negative breast cancer
Summary of current combinations for TNBC treatment in clinical trials. The therapeutic strategies include immunotherapy and various molecular targeted therapies, including intracellular pathway inhibitors, cell cycle inhibitors, and AR inhibitors. ADCs: antibody‒drug conjugates; BRD4: bromodomain containing 4; ICB: immune checkpoint blockade; mAb: monoclonal antibody; and PARP: poly-adenosine diphosphate ribose polymerase